BYU research yields compound that appears to slow aging effects in skin

March 16, 2010
BYU research yields compound that appears to slow aging effects in skin
A skin serum sold by Nu Skin includes the molecule identified by Lephart.

(PhysOrg.com) -- BYU research has identified equol as a naturally occurring compound that improves skin health, and the university has licensed the technology to Provo-based Nu Skin Enterprises, the $1.3 billion global anti-aging personal care and nutritional products company.

The anti-aging skin product that features the BYU ingredient was launched in October as part of the company’s ageLOC(TM) skin care line. Nu Skin sold $28 million of ageLOC skin care products in the last quarter of 2009.

The little-known molecule, called equol, is derived from plants such as soybeans. Its benefits for skin grew out of earlier work by BYU Professor Edwin Lephart who was testing various compounds from plants for possible impacts on human health. Equol stood out.

“When we discovered how equol acts and what its properties are, of all the sites in the body where it could be active, skin just jumped out to me,” said Lephart, who was a faculty member at the University of Texas Southwestern Medical Center before coming to BYU in the 1990s.

He and colleagues published three research papers on equol’s wide-ranging potential to impact prostate health, skin, baldness, weight gain, and brain health.

Lephart prepared further experiments to test its influence on two important components of skin: collagen, which gives skin its structure, and elastin, which gives skin the flexibility to resume its shape after stretching or contracting. The work relied on a technique that cultures dermal cells in the lab to resemble , and some tests lasted as long as eight weeks.

“We asked, ‘What would equol do if we added it to the that make collagen and elastin - would it stimulate them?’” Lephart said. “And it does.”

Just as importantly, the research showed equol also inhibits other enzymes that break down elastin and collagen.

“So we get an increase in collagen and elastin, and we take away the enzymes that break them down, which is really cool,” said Lephart, of BYU’s Department of Physiology and Developmental Biology.

This skin-specific work was presented at two annual meetings of the American Academy of Dermatology, a premier scientific meeting of world-renowned leaders in the field.

The university licensed to Nu Skin rights to sell equol in a cosmetic skin care product.

Nu Skin’s product that includes equol is called ageLOC Future Serum, and is the stand-out product in the ageLOC Transformation daily skin care line.

BYU’s equol-related technologies are patent-pending. Lephart was the principal investigator on the studies that led to these patent applications, and he collaborated with researchers at Colorado State University and Cincinnati Children’s Hospital Medical Center. Those institutions receive a share of the royalties generated by the BYU license.

BYU negotiators are also working to license the rights to use equol to treat conditions other than skin health to other companies.

Related Stories

Recommended for you

How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis

November 21, 2017
Drug designers working on therapeutics against multiple sclerosis should focus on blocking two distinct ways rogue immune cells attack healthy neurons, according to a new study in the journal Cell Reports.

Cinnamon turns up the heat on fat cells

November 21, 2017
New research from the University of Michigan Life Sciences Institute has determined how a common holiday spice—cinnamon—might be enlisted in the fight against obesity.

New simple test could help cystic fibrosis patients find best treatment

November 21, 2017
Several cutting-edge treatments have become available in recent years to correct the debilitating chronic lung congestion associated with cystic fibrosis. While the new drugs are life-changing for some patients, they do not ...

Researchers discover key signaling protein for muscle growth

November 20, 2017
Researchers at the University of Louisville have discovered the importance of a well-known protein, myeloid differentiation primary response gene 88 (MyD88), in the development and regeneration of muscles. Ashok Kumar, Ph.D., ...

New breast cell types discovered by multidisciplinary research team

November 20, 2017
A joint effort by breast cancer researchers and bioinformaticians has provided new insights into the molecular changes that drive breast development.

Brain cell advance brings hope for Creutzfeldt-Jakob disease

November 20, 2017
Scientists have developed a new system to study Creutzfeldt-Jakob disease in the laboratory, paving the way for research to find treatments for the fatal brain disorder.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.